Clinical Trial Update: A Repeated-Dose Evaluation of a Pain Relieving Drug Use and Safety of OROS Hydromorphone HCI in Patients With Chronic Non-Malignant Pain [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating repeated-dose safety and efficacy of OROS Hydromorphone HCl for chronic non-malignant pain.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-malignant Pain

Drugs mentioned

• OROS Hydromorphone HCl (Hydromorphone hydrochloride)

Snippet

Sponsor: Alza Corporation, DE, USA | Conditions: Pain, Analgesics | Phase 3 | Status: COMPLETED